| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3979306 | Bulletin du Cancer | 2010 | 12 Pages |
Abstract
FET is a radiopharmaceutical with clinical usefulness for the diagnosis, delineation and monitoring of brain tumours. Association with FDG allows identification of high-grade lesions or components, but it could be avoided providing that acquisition and quantification procedures of FET PET/CT would have been better optimised and standardised.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
V. Nataf, K. Kerrou, S. Balogova, F. Pene, V. Huchet, F. Gutman, A. Prignon, I.-P. Muresan, C. Giannesini, V. Izrael, M. Schlienger, J.-N. Talbot,